IR@PKUHSC  > 北京大学第二临床医学院  > 肾内科
学科主题临床医学
Lanthanum carbonate for the treatment of hyperphosphatemia in CKD 5D: multicenter, double blind, randomized, controlled trial in mainland China
Xu, Jing1; Zhang, Yi-Xiang1; Yu, Xue-Qing2; Liu, Zhi-Hong3; Wang, Li-Ning4; Chen, Jiang-Hua5; Fan, Ya-Ping6; Ni, Zhao-Hui7; Wang, Mei8; Yuan, Fa-Huan9,10; Ding, Guo-Hua11; Chen, Xiang-Mei12,13; Zhang, Ai-Ping14; Mei, Chang-Lin1
关键词Lanthanum Carbonate Hyperphosphatemia Chronic Kidney Disease 5d Hemodialysis Continuous Ambulatory Peritoneal Dialysis (Capd)
刊名BMC NEPHROLOGY
2013-02-04
DOI10.1186/1471-2369-14-29
14
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Urology & Nephrology
研究领域[WOS]Urology & Nephrology
关键词[WOS]CHRONIC KIDNEY-DISEASE ; CHRONIC-HEMODIALYSIS PATIENTS ; ORAL PHOSPHATE BINDERS ; SERUM-CALCIUM LEVELS ; MORTALITY RISK ; DIALYSIS PATIENTS ; PHOSPHORUS ; EFFICACY ; ASSOCIATION ; FAILURE
英文摘要

Background: Serum phosphorus control is critical for chronic kidney disease (CKD) 5D patients. Currently, clinical profile for an oral phosphorus binder in the mainland Chinese population is not available.

Objective: To establish the efficacy, safety, and tolerability of lanthanum carbonate in CKD 5D patients.

Design: Multicenter, randomized, double blind, placebo-controlled study. A central randomization center used computer generated tables to allocate treatments.

Setting: Twelve tertiary teaching hospitals and medical university affiliated hospitals in mainland China.

Participants: Overall, 258 hemodialysis or continuous ambulatory peritoneal dialysis (CAPD) adult patients were enrolled.

Intervention: After a 0-3-week washout period and a 4-week lanthanum carbonate dose-titration period, 230 patients were randomized 1: 1 to receive lanthanum carbonate (1500 mg-3000 mg) or placebo for a further 4-week maintenance phase.

Main outcome measures: Efficacy and safety of lanthanum carbonate to achieve and maintain target serum phosphorus concentrations were assessed.

Results: In the titration phase, serum phosphorus concentrations of all patients decreased significantly. About three-fifths achieved target levels without significantly disturbing serum calcium levels. At the end of the maintenance period, the mean difference in serum phosphorus was significantly different between the lanthanum carbonate and placebo-treated groups (0.63+/-0.62 mmol/L vs. 0.15+/-0.52 mmol/L, P < 0.001). The drug-related adverse effects were mild and mostly gastrointestinal in nature.

Conclusion: Lanthanum carbonate is an efficacious and well-tolerated oral phosphate binder with a mild AE profile in hemodialysis and CAPD patients. This agent may provide an alternative for the treatment of hyperphosphatemia in CKD 5D patients in mainland China.

语种英语
WOS记录号WOS:000314833700001
引用统计
被引频次:11[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/53891
专题北京大学第二临床医学院_肾内科
作者单位1.Mil Med Postgrad Coll, Beijing, Peoples R China
2.Second Mil Med Univ, Changzheng Hosp, Dept Nephrol, Shanghai, Peoples R China
3.Sun Yat Sen Univ, Affiliated Hosp 1, Dept Nephrol, Guangzhou, Guangdong, Peoples R China
4.Nanjing Univ, Jingling Hosp, Sch Med, Dept Nephrol,Inst Kidney Dis Chinese Peoples Libe, Nanjing 210008, Jiangsu, Peoples R China
5.China Med Univ, Affiliated Hosp 1, Dept Nephrol, Shenyang, Peoples R China
6.Zhejiang Univ, Affiliated Hosp 1, Coll Med, Kidney Dis Ctr, Hangzhou 310003, Zhejiang, Peoples R China
7.Nantong Med Coll, Affiliated Hosp, Dept Nephrol, Nantong, Jiangsu, Peoples R China
8.Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Div Renal, Shanghai 200030, Peoples R China
9.Peking Univ, Peoples Hosp, Dept Nephrol, Beijing 100871, Peoples R China
10.Third Mil Med Univ, Xinqiao Hosp, Inst Nephrol Chongqing, Chongqing, Peoples R China
11.Third Mil Med Univ, Xinqiao Hosp, Dept Nephrol, Chongqing, Peoples R China
12.Wuhan Univ, Renmin Hosp, Dept Nephrol, Wuhan 430072, Peoples R China
13.Chinese Peoples Liberat Army Gen Hosp, Chinese PLA Inst Nephrol, Beijing, Peoples R China
14.Gen Hosp Jinan Mil Command, Dept Nephrol, Jinan, Shandong, Peoples R China
推荐引用方式
GB/T 7714
Xu, Jing,Zhang, Yi-Xiang,Yu, Xue-Qing,et al. Lanthanum carbonate for the treatment of hyperphosphatemia in CKD 5D: multicenter, double blind, randomized, controlled trial in mainland China[J]. BMC NEPHROLOGY,2013,14.
APA Xu, Jing.,Zhang, Yi-Xiang.,Yu, Xue-Qing.,Liu, Zhi-Hong.,Wang, Li-Ning.,...&Mei, Chang-Lin.(2013).Lanthanum carbonate for the treatment of hyperphosphatemia in CKD 5D: multicenter, double blind, randomized, controlled trial in mainland China.BMC NEPHROLOGY,14.
MLA Xu, Jing,et al."Lanthanum carbonate for the treatment of hyperphosphatemia in CKD 5D: multicenter, double blind, randomized, controlled trial in mainland China".BMC NEPHROLOGY 14(2013).
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Xu, Jing]的文章
[Zhang, Yi-Xiang]的文章
[Yu, Xue-Qing]的文章
百度学术
百度学术中相似的文章
[Xu, Jing]的文章
[Zhang, Yi-Xiang]的文章
[Yu, Xue-Qing]的文章
必应学术
必应学术中相似的文章
[Xu, Jing]的文章
[Zhang, Yi-Xiang]的文章
[Yu, Xue-Qing]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。